Induction of tumor immunity by variants of folate binding protein
The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness.
1. A method of inducing immunity against a cancer expressing folate binding protein (SEQ ID NO:10) in an individual, the method comprising administering to the individual an effective amount a first vaccine composition comprising a peptide consisting of the amino acid sequence EIWTFSTKV (SEQ ID NO: 5).
2. The method of claim 1 , further comprising administering a second vaccine composition comprising a peptide consisting of the amino acid sequence EIWTHSYKV (SEQ ID NO: 268).
3. The method of claim 2 , wherein the first vaccine composition is administered prior to the administration of the second composition.
4. The method of claim 2 , wherein the second vaccine composition is administered prior to the administration of the first composition.
5. The method of claim 1 , wherein the first vaccine composition further comprises an adjuvant.
6. The method of claim 2 , wherein the second vaccine composition further comprises an adjuvant.
7. The method of claim 1 , wherein the first vaccine composition is formulated for intradermal, subcutaneous or intravenous administration.
8. The method of claim 2 , wherein the second vaccine composition is formulated for intradermal, subcutaneous or intravenous administration.
9. The method of claim 1 , further comprising multiple administrations of the first peptide vaccine at two to twelve week intervals.
10. The method of claim 2 , further comprising multiple administration of the second peptide vaccine at two to twelve week intervals.
11. The method of claim 1 , further comprising administering a booster composition comprising a peptide consisting of amino acid sequence EIWTFSTKV (SEQ ID NO: 5).
12. The method of claim 1 , further comprising administering a booster composition comprising a peptide consisting of amino acid sequence EIWTHSYKV (SEQ ID NO: 268).
13. The method of claim 2 , further comprising administering a booster composition comprising a peptide consisting of amino acid sequence EIWTFSTKV (SEQ ID NO: 5).
14. The method of claim 2 , further comprising administering a booster composition comprising a peptide consisting of amino acid sequence EIWTHSYKV (SEQ ID NO: 268).
15. The method of claim 1 , wherein the cancer is breast cancer, ovarian cancer, endometrial cancer, colorectal cancer, lung cancer, renal cancer, melanoma, kidney cancer, prostate cancer, brain cancer, sarcomas, or a combination thereof.
16. The method of claim 2 , wherein the cancer is breast cancer, ovarian cancer, endometrial cancer, colorectal cancer, lung cancer, renal cancer, melanoma, kidney cancer, prostate cancer, brain cancer, sarcomas, or a combination thereof.
17. A method of inducing immunity against a cancer expressing folate binding protein (SEQ ID NO:10) in an individual, the method comprising administering to the individual an effective amount a first vaccine composition comprising a peptide consisting of the amino acid sequence EIWTFSTKV (SEQ ID NO: 5), and subsequently administering an effective amount of a second vaccine composition comprising a peptide consisting of the amino acid sequence EIWTHSYKV (SEQ ID NO: 268).
18. The method of claim 17 , wherein the first vaccine composition and the second vaccine composition further comprise an adjuvant.
19. The method of claim 17 , wherein the first vaccine composition and the second vaccine composition are formulated for intradermal, subcutaneous or intravenous administration.
20. The method of claim 17 , further comprising administering a booster composition comprising a peptide consisting of amino acid sequence EIWTFSTKV (SEQ ID NO: 5).
21. The method of claim 17 , further comprising administering a booster composition comprising a peptide consisting of amino acid sequence EIWTHSYKV (SEQ ID NO: 268).
22. The method of claim 17 , wherein the cancer is breast cancer, ovarian cancer, endometrial cancer, colorectal cancer, lung cancer, renal cancer, melanoma, kidney cancer, prostate cancer, brain cancer, sarcomas, or a combination thereof.
23. A method of inducing immunity against a cancer expressing folate binding protein (SEQ ID NO:10) in an individual, the method comprising administering to the individual an effective amount a first vaccine composition comprising a peptide consisting of the amino acid sequence EIWTHSYKV (SEQ ID NO: 268), and subsequently administering an effective amount of a second vaccine composition comprising a peptide consisting of the amino acid sequence EIWTFSTKV (SEQ ID NO: 5).
24. The method of claim 23 , wherein the first vaccine composition and the second vaccine composition further comprise an adjuvant.
25. The method of claim 23 , wherein the first vaccine composition and the second vaccine composition are formulated for intradermal, subcutaneous or intravenous administration.
26. The method of claim 23 , further comprising administering a booster composition comprising a peptide consisting of amino acid sequence EIWTFSTKV (SEQ ID NO: 5).
27. The method of claim 23 , further comprising administering a booster composition comprising a peptide consisting of amino acid sequence EIWTHSYKV (SEQ ID NO: 268).
28. The method of claim 23 , wherein the cancer is breast cancer, ovarian cancer, endometrial cancer, colorectal cancer, lung cancer, renal cancer, melanoma, kidney cancer, prostate cancer, brain cancer, sarcomas, or a combination thereof.